Company registration number 11018685 (England and Wales)
CHRYSALIS HEALTHCARE GROUP LTD
ANNUAL REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025
PAGES FOR FILING WITH REGISTRAR
CHRYSALIS HEALTHCARE GROUP LTD
COMPANY INFORMATION
Directors
W Harris
M Gilbert
Company number
11018685
Registered office
1 Worsley Court
High Street
Worsley
Manchester
M28 3NJ
Auditor
Champion Accountants LLP
1 Worsley Court
High Street
Worsley
Manchester
M28 3NJ
CHRYSALIS HEALTHCARE GROUP LTD
CONTENTS
Page
Group balance sheet
1
Company balance sheet
2
Group statement of changes in equity
3
Company statement of changes in equity
4
Notes to the financial statements
5 - 17
CHRYSALIS HEALTHCARE GROUP LTD
GROUP BALANCE SHEET
AS AT
31 MARCH 2025
31 March 2025
- 1 -
2025
2024
Notes
£
£
£
£
Fixed assets
Intangible assets
4
1,136,126
1,407,261
Tangible assets
5
20,339
23,740
1,156,465
1,431,001
Current assets
Debtors
8
65,265,379
506,220
Investments
9
2,408,545
-
0
Cash at bank and in hand
6,896,628
77,418
74,570,552
583,638
Creditors: amounts falling due within one year
10
(6,344,543)
(840,119)
Net current assets/(liabilities)
68,226,009
(256,481)
Total assets less current liabilities
69,382,474
1,174,520
Creditors: amounts falling due after more than one year
11
(71,536,580)
(50,000)
Provisions for liabilities
(3,757)
(3,757)
Net (liabilities)/assets
(2,157,863)
1,120,763
Capital and reserves
Called up share capital
1,000
1,000
Profit and loss reserves
13
(2,158,863)
1,119,763
Total equity
(2,157,863)
1,120,763

The directors of the group have elected not to include a copy of the profit and loss account within the financial statements.

These financial statements have been prepared in accordance with the provisions applicable to groups and companies subject to the small companies regime.

The financial statements were approved by the board of directors and authorised for issue on 26 November 2025 and are signed on its behalf by:
26 November 2025
W Harris
Director
Company registration number 11018685 (England and Wales)
CHRYSALIS HEALTHCARE GROUP LTD
COMPANY BALANCE SHEET
AS AT 31 MARCH 2025
31 March 2025
- 2 -
2025
2024
Notes
£
£
£
£
Fixed assets
Intangible assets
4
94,389
89,838
Tangible assets
5
363
-
0
Investments
6
1,076,052
1,076,052
1,170,804
1,165,890
Current assets
Debtors
8
52,525
23,496
Cash at bank and in hand
23,119
11,522
75,644
35,018
Creditors: amounts falling due within one year
10
(1,680,739)
(1,204,150)
Net current liabilities
(1,605,095)
(1,169,132)
Net liabilities
(434,291)
(3,242)
Capital and reserves
Called up share capital
1,000
1,000
Merger reserve
13
399,000
399,000
Profit and loss reserves
13
(834,291)
(403,242)
Total equity
(434,291)
(3,242)

As permitted by s408 Companies Act 2006, the company has not presented its own profit and loss account and related notes. The company’s loss for the year was £431,049 (2024 - £242,220 loss).

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the board of directors and authorised for issue on 26 November 2025 and are signed on its behalf by:
26 November 2025
W Harris
Director
Company Registration No. 11018685
CHRYSALIS HEALTHCARE GROUP LTD
GROUP STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 MARCH 2025
- 3 -
Share capital
Profit and loss reserves
Total
£
£
£
Balance at 1 April 2023
1,000
1,582,026
1,583,026
Year ended 31 March 2024:
Loss and total comprehensive income
-
(462,263)
(462,263)
Balance at 31 March 2024
1,000
1,119,763
1,120,763
Year ended 31 March 2025:
Loss and total comprehensive income
-
(3,278,626)
(3,278,626)
Balance at 31 March 2025
1,000
(2,158,863)
(2,157,863)
CHRYSALIS HEALTHCARE GROUP LTD
COMPANY STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 MARCH 2025
- 4 -
Share capital
Merger reserve
Profit and loss reserves
Total
£
£
£
£
Balance at 1 April 2023
1,000
399,000
(161,022)
238,978
Year ended 31 March 2024:
Loss and total comprehensive income for the year
-
-
(242,220)
(242,220)
Balance at 31 March 2024
1,000
399,000
(403,242)
(3,242)
Year ended 31 March 2025:
Profit and total comprehensive income
-
-
(431,049)
(431,049)
Balance at 31 March 2025
1,000
399,000
(834,291)
(434,291)
CHRYSALIS HEALTHCARE GROUP LTD
NOTES TO THE GROUP FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025
- 5 -
1
Accounting policies
Company information

Chrysalis Healthcare Group Limited (“the company”) is a private limited company domiciled and incorporated in England and Wales. The registered office is 1 Worsley Court, High Street, Worsley, Manchester, M28 3NJ.

 

The group consists of Chrysalis Healthcare Group Limited and all of its subsidiaries.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, The principal accounting policies adopted are set out below.

The company is a qualifying entity for the purposes of FRS 102, being a member of a group where the parent of that group prepares publicly available consolidated financial statements, including this company, which are intended to give a true and fair view of the assets, liabilities, financial position and profit or loss of the group. The company has therefore taken advantage of exemptions from the following disclosure requirements for parent company information presented within the consolidated financial statements:

 

1.2
Business combinations

In the parent company financial statements, the cost of a business combination is the fair value at the acquisition date of the assets given, equity instruments issued and liabilities incurred or assumed, plus costs directly attributable to the business combination. The excess of the cost of a business combination over the fair value of the identifiable assets, liabilities and contingent liabilities acquired is recognised as goodwill. The cost of the combination includes the estimated amount of contingent consideration that is probable and can be measured reliably, and is adjusted for changes in contingent consideration after the acquisition date. Provisional fair values recognised for business combinations in previous periods are adjusted retrospectively for final fair values determined in the 12 months following the acquisition date. Investments in subsidiaries, joint ventures and associates are accounted for at cost less impairment.

 

Deferred tax is recognised on differences between the value of assets (other than goodwill) and liabilities recognised in a business combination accounted for using the purchase method and the amounts that can be deducted or assessed for tax, considering the manner in which the carrying amount of the asset or liability is expected to be recovered or settled. The deferred tax recognised is adjusted against goodwill or negative goodwill.

CHRYSALIS HEALTHCARE GROUP LTD
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
1
Accounting policies
(Continued)
- 6 -
1.3
Basis of consolidation

The consolidated group financial statements consist of the financial statements of the parent company Chrysalis Healthcare Group Limited together with all entities controlled by the parent company (its subsidiaries) and the group’s share of its interests in joint ventures and associates.

 

All financial statements are made up to 31 March 2025. Where necessary, adjustments are made to the financial statements of subsidiaries to bring the accounting policies used into line with those used by other members of the group.

 

All intra-group transactions, balances and unrealised gains on transactions between group companies are eliminated on consolidation. Unrealised losses are also eliminated unless the transaction provides evidence of an impairment of the asset transferred.

Subsidiaries are consolidated in the group’s financial statements from the date that control commences until the date that control ceases.

Entities in which the group holds an interest and which are jointly controlled by the group and one or more other venturers under a contractual arrangement are treated as joint ventures. Entities other than subsidiary undertakings or joint ventures, in which the group has a participating interest and over whose operating and financial policies the group exercises a significant influence, are treated as associates.

Investments in joint ventures and associates are carried in the group balance sheet at cost plus post-acquisition changes in the group’s share of the net assets of the entity, less any impairment in value. The carrying values of investments in joint ventures and associates include acquired goodwill.

 

If the group’s share of losses in a joint venture or associate equals or exceeds its investment in the joint venture or associate, the group does not recognise further losses unless it has incurred obligations to do so or has made payments on behalf of the joint venture or associate.

 

Unrealised gains arising from transactions with joint ventures and associates are eliminated to the extent of the group’s interest in the entity.

1.4
Going concern

In 2024, Chrysalis Finance made the strategic decision to transition from a broking model to a direct lending model, building its own loan portfolio. This was a medium to long-term decision designed to secure access to lower cost of funds and resilience through securitisation, thereby improving future profitability and funding certainty.

The decision is common in the market, with similar transitional effects typically seen before businesses reach profitability post the initial investment phase.

Financial forecasts, prepared in collaboration with our debt providers, project that the business will reach breakeven in Q4 2025. These funders have committed sufficient working capital facilities to support the company through the transition period and have strongly aligned financial incentives in the long-term success of the business.

The company has already seen strong growth in origination volumes and continues to perform on track to meet or exceed its business objectives.

Accordingly, the Directors believe the company has both the funding support and a credible plan in place to meet its obligations as they fall due and to continue operating as a going concern

CHRYSALIS HEALTHCARE GROUP LTD
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
1
Accounting policies
(Continued)
- 7 -
1.5
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

 

When cash inflows are deferred and represent a financing arrangement, the fair value of the consideration is the present value of the future receipts. The difference between the fair value of the consideration and the nominal amount received is recognised as interest income.

 

The principles for recognising income from consumer lending activities, ensuring accuracy, consistency, and compliance with applicable financial reporting standards (FRS 102) and regulatory guidelines (e.g. FCA CONC). It includes specific provisions for recognising subsidy income from 0% APR lending agreements at point of sale (POS).

The company recognises revenue from the following major sources:

 

Recognised using the advertised APR of the loan. The APR is decompounded to a periodic rate which is calculated daily on the current outstanding balance, including any previously unpaid interest, and charged to the borrower’s account monthly.

 

The APR reflects all interest, fees and charges (see section below on fees and charges) that are integral to the loan yield, including origination costs.

 

Accrual begins from the disbursement date and ends upon full settlement, write-off, or derecognition.

 

For lower APR credit offers, the merchant or retailer accepts a lower payment from the lender for the work being carried out. The differential between the sum the borrower finances and the amount paid to the retailer is the subsidy. This subsidy helps the ender over a reduced interest rate to the borrower.

 

This subsidy is recognised as interest income under the Effective Interest Rate method over the life of the loan, as it compensates the lender for foregone interest. The full value of the subsidy is deferred and amortised over the loan term using the EIR method to calculate the recovery rate.

 

Subsidy recovery only occurs when borrower make a sufficient repayment to reduce their outstanding capital amount. Should they only pay enough to cover existing interest, no subsidy recovery occurs.

Where loans are repaid early, unamortised income (interest or fees) is recognised immediately.

Any required rebates to the consumer are processed in accordance with the Consumer Credit Act and FCA regulations.

 

The residual difference between the current outstanding balance and the settlement figure is the early settlement interest and is charged to the P&L immediately.

 

Should a loan be adjusted to a lower amount, any additional interest that has accrued on the loan due to the adjustment will be refunded to the customer and the amount debited to the P&L.

 

Where customers have made repayments before a cancellation, these repayments will be refunded to the customer, and any attributable interest or subsidy recovery will be debited from the P&L.

CHRYSALIS HEALTHCARE GROUP LTD
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
1
Accounting policies
(Continued)
- 8 -

A loan is considered non-performing when it is more than 90 days past due or otherwise considered unlikely to pay.

 

From this point, interest income is no longer accrued and is only recognised on a cash basis.

Subsequent recovery of any interest will be assessed on a case by case basis.

 

Income is recognised net of impairments. Any provisions or write offs will be debited from the P&L. Regular reviews and model updates are required in line with IFRS 9/FRS 102 principles and FCA risk expectations.

 

The group brokers some of its credit applications to third party lenders, which pay commission to the group for each loan they pay out.

1.6
Intangible fixed assets - goodwill

Goodwill represents the excess of the cost of acquisition of a business over the fair value of net assets acquired. It is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is considered to have a finite useful life and is amortised on a systematic basis over its expected life, which is ten years.

 

For the purposes of impairment testing, goodwill is allocated to the cash-generating units expected to benefit from the acquisition. Cash-generating units to which goodwill has been allocated are tested for impairment at least annually, or more frequently when there is an indication that the unit may be impaired. If the recoverable amount of the cash-generating unit is less than the carrying amount of the unit, the impairment loss is allocated first to reduce the carrying amount of any goodwill allocated to the unit and then to the other assets of the unit pro-rata on the basis of the carrying amount of each asset in the unit.

1.7
Intangible fixed assets other than goodwill

Intangible assets acquired separately from a business are recognised at cost and are subsequently measured at cost less accumulated amortisation and accumulated impairment losses.

 

Intangible assets acquired on business combinations are recognised separately from goodwill at the acquisition date where it is probable that the expected future economic benefits that are attributable to the asset will flow to the entity and the fair value of the asset can be measured reliably; the intangible asset arises from contractual or other legal rights; and the intangible asset is separable from the entity.

Amortisation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Software
Seven years straight line
1.8
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Fixtures and fittings
25% Straight line
Computers
25% Straight line
CHRYSALIS HEALTHCARE GROUP LTD
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
1
Accounting policies
(Continued)
- 9 -

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in the profit and loss account.

1.9
Fixed asset investments

Equity investments are measured at fair value through profit or loss, except for those equity investments that are not publicly traded and whose fair value cannot otherwise be measured reliably, which are recognised at cost less impairment until a reliable measure of fair value becomes available.

 

In the parent company financial statements, investments in subsidiaries, associates and jointly controlled entities are initially measured at cost and subsequently measured at cost less any accumulated impairment losses.

A subsidiary is an entity controlled by the group. Control is the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities.

An associate is an entity, being neither a subsidiary nor a joint venture, in which the company holds a long-term interest and where the company has significant influence. The group considers that it has significant influence where it has the power to participate in the financial and operating decisions of the associate.

 

Investments in associates are initially recognised at the transaction price (including transaction costs) and are subsequently adjusted to reflect the group’s share of the profit or loss, other comprehensive income and equity of the associate using the equity method. Any difference between the cost of acquisition and the share of the fair value of the net identifiable assets of the associate on acquisition is recognised as goodwill. Any unamortised balance of goodwill is included in the carrying value of the investment in associates.

 

Losses in excess of the carrying amount of an investment in an associate are recorded as a provision only when the company has incurred legal or constructive obligations or has made payments on behalf of the associate.

 

In the parent company financial statements, investments in associates are accounted for at cost less impairment.

1.10
Impairment of fixed assets

At each reporting period end date, the group reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

 

The carrying amount of the investments accounted for using the equity method is tested for impairment as a single asset. Any goodwill included in the carrying amount of the investment is not tested separately for impairment.

Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.

 

If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.

CHRYSALIS HEALTHCARE GROUP LTD
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
1
Accounting policies
(Continued)
- 10 -

Recognised impairment losses are reversed if, and only if, the reasons for the impairment loss have ceased to apply. Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.

1.11
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.12
Financial instruments

The group has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the group's balance sheet when the group becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset and the net amounts presented in the financial statements when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Other financial assets

Other financial assets, including investments in equity instruments which are not subsidiaries, associates or joint ventures, are initially measured at fair value, which is normally the transaction price. Such assets are subsequently carried at fair value and the changes in fair value are recognised in profit or loss, except that investments in equity instruments that are not publicly traded and whose fair values cannot be measured reliably are measured at cost less impairment.

Impairment of financial assets

Financial assets, other than those held at fair value through profit and loss, are assessed for indicators of impairment at each reporting end date.

 

Financial assets are impaired where there is objective evidence that, as a result of one or more events that occurred after the initial recognition of the financial asset, the estimated future cash flows have been affected. If an asset is impaired, the impairment loss is the difference between the carrying amount and the present value of the estimated cash flows discounted at the asset’s original effective interest rate. The impairment loss is recognised in profit or loss.

 

If there is a decrease in the impairment loss arising from an event occurring after the impairment was recognised, the impairment is reversed. The reversal is such that the current carrying amount does not exceed what the carrying amount would have been, had the impairment not previously been recognised. The impairment reversal is recognised in profit or loss.

CHRYSALIS HEALTHCARE GROUP LTD
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
1
Accounting policies
(Continued)
- 11 -
Derecognition of financial assets

Financial assets are derecognised only when the contractual rights to the cash flows from the asset expire or are settled, or when the group transfers the financial asset and substantially all the risks and rewards of ownership to another entity, or if some significant risks and rewards of ownership are retained but control of the asset has transferred to another party that is able to sell the asset in its entirety to an unrelated third party.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the group after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

 

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Other financial liabilities

Derivatives, including interest rate swaps and forward foreign exchange contracts, are not basic financial instruments. Derivatives are initially recognised at fair value on the date a derivative contract is entered into and are subsequently re-measured at their fair value. Changes in the fair value of derivatives are recognised in profit or loss in finance costs or finance income as appropriate, unless hedge accounting is applied and the hedge is a cash flow hedge.

 

Debt instruments that do not meet the conditions in FRS 102 paragraph 11.9 are subsequently measured at fair value through profit or loss. Debt instruments may be designated as being measured at fair value through profit or loss to eliminate or reduce an accounting mismatch or if the instruments are measured and their performance evaluated on a fair value basis in accordance with a documented risk management or investment strategy.

Derecognition of financial liabilities

Financial liabilities are derecognised when the group's contractual obligations expire or are discharged or cancelled.

1.13
Equity instruments

Equity instruments issued by the group are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the group.

1.14
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

CHRYSALIS HEALTHCARE GROUP LTD
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
1
Accounting policies
(Continued)
- 12 -
Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The group’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

 

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset if, and only if, there is a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

1.15
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

 

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.16
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

2
Judgements and key sources of estimation uncertainty

In the application of the group’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

 

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

CHRYSALIS HEALTHCARE GROUP LTD
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
- 13 -
3
Employees

The average monthly number of persons (including directors) employed by the group and company during the year was:

Group
Company
2025
2024
2025
2024
Number
Number
Number
Number
Total
39
31
2
2
4
Intangible fixed assets
Group
Goodwill
Negative goodwill
Software
Total
£
£
£
£
Cost
At 1 April 2024
629,079
(278,445)
1,840,169
2,190,803
Additions - internally developed
-
0
-
0
56,224
56,224
At 31 March 2025
629,079
(278,445)
1,896,393
2,247,027
Amortisation and impairment
At 1 April 2024
204,451
(278,445)
857,536
783,542
Amortisation charged for the year
62,908
-
0
264,451
327,359
At 31 March 2025
267,359
(278,445)
1,121,987
1,110,901
Carrying amount
At 31 March 2025
361,720
-
0
774,406
1,136,126
At 31 March 2024
424,628
-
0
982,633
1,407,261
Company
Software
£
Cost
At 1 April 2024
104,811
Additions - internally developed
20,000
At 31 March 2025
124,811
Amortisation and impairment
At 1 April 2024
14,973
Amortisation charged for the year
15,449
At 31 March 2025
30,422
CHRYSALIS HEALTHCARE GROUP LTD
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
4
Intangible fixed assets
(Continued)
- 14 -
Carrying amount
At 31 March 2025
94,389
At 31 March 2024
89,838
5
Tangible fixed assets
Group
Plant and machinery etc
£
Cost
At 1 April 2024
514,528
Additions
8,281
At 31 March 2025
522,809
Depreciation and impairment
At 1 April 2024
490,788
Depreciation charged in the year
11,682
At 31 March 2025
502,470
Carrying amount
At 31 March 2025
20,339
At 31 March 2024
23,740
Company
Plant and machinery etc
£
Cost
At 1 April 2024
-
0
Additions
447
At 31 March 2025
447
Depreciation and impairment
At 1 April 2024
-
0
Depreciation charged in the year
84
At 31 March 2025
84
Carrying amount
At 31 March 2025
363
CHRYSALIS HEALTHCARE GROUP LTD
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
- 15 -
6
Fixed asset investments
Group
Company
2025
2024
2025
2024
£
£
£
£
Shares in group undertakings and participating interests
-
-
1,076,052
1,076,052
Movements in fixed asset investments
Company
Shares in subsidiaries
£
Cost or valuation
At 1 April 2024 and 31 March 2025
1,076,052
Carrying amount
At 31 March 2025
1,076,052
At 31 March 2024
1,076,052
7
Subsidiaries
Name of undertaking
Registered office
Class of
% Held
shares held
Direct
Indirect
Chrysalis Finance Limited
England & Wales
Ordinary Shares
100.00
-
Financing First Limited
England & Wales
Ordinary Shares
100.00
-
Chrysalis Dental Finance Limited (Dormant)
England & Wales
Ordinary Shares
0
100.00
Chrysalis Medical Finance Limited (Dormant)
England & Wales
Ordinary Shares
0
100.00
Chrysalis Technical Services Limited (Dormant)
England & Wales
Ordinary Shares
0
100.00
Zebra Health Finance Limited (Dormant)
England & Wales
Ordinary Shares
0
100.00
Treatmentpay Limited
England & Wales
Ordinary Shares
100.00
-
8
Debtors
Group
Company
2025
2024
2025
2024
Amounts falling due within one year:
£
£
£
£
Trade debtors
1,703
13,991
-
0
-
0
Other debtors
1,670,597
492,229
52,525
23,496
Loan book debtors
63,593,079
-
0
-
0
-
0
65,265,379
506,220
52,525
23,496
CHRYSALIS HEALTHCARE GROUP LTD
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
- 16 -
9
Current asset investments
Group
Company
2025
2024
2025
2024
£
£
£
£
Loans
2,408,545
-
-
-
10
Creditors: amounts falling due within one year
Group
Company
2025
2024
2025
2024
£
£
£
£
Other borrowings
12
40,000
57,625
-
0
-
0
Trade creditors
261,077
319,779
109,693
41,820
Amounts owed to group undertakings
-
0
-
0
1,558,751
1,129,166
Corporation tax payable
360
63,841
-
0
-
0
Other taxation and social security
215,475
95,379
-
3,281
Other creditors
350,312
30,900
-
0
-
0
Accruals and deferred income
5,477,319
272,595
12,295
29,883
6,344,543
840,119
1,680,739
1,204,150
11
Creditors: amounts falling due after more than one year
Group
Company
2025
2024
2025
2024
Notes
£
£
£
£
Other borrowings
12
10,000
50,000
-
0
-
0
Other creditors
71,526,580
-
0
-
0
-
0
71,536,580
50,000
-
-
12
Loans and overdrafts
Group
Company
2025
2024
2025
2024
£
£
£
£
Other loans
50,000
107,625
-
-
Payable within one year
40,000
57,625
-
-
Payable after one year
10,000
50,000
-
0
-
0

 

Other loans consist of CBILS loans which are secured by fixed and floating charges over the assets of the group.

CHRYSALIS HEALTHCARE GROUP LTD
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
- 17 -
13
Reserves
Profit and loss reserves

This reserve records retained earnings and accumulated losses.

Merger reserve

Merger reserve represents the difference between the value of shares issued by the company in exchange for the value of shares acquired in respect of the acquisition of subsidiaries.

14
Audit report information

As the income statement has been omitted from the filing copy of the financial statements, the following information in relation to the audit report on the statutory financial statements is provided in accordance with s444(5B) of the Companies Act 2006.

The auditor's report is unqualified and includes the following:

Opinion

In our opinion the financial statements:

Senior Statutory Auditor:
Mark Turner FCA
Statutory Auditor:
Champion Accountants LLP
Date of audit report:
26 November 2025
15
Related party transactions

The group has taken advantage of the provisions available at paragraph 33.1A of FRS 102, not to disclose transactions between wholly owned group members.

 

By virtue of common directorships and shareholdings, Whitebarn Farm Limited is a related party. During the year the group paid storage charges of £56,667 (2024: £33,333) and owed an amount of £21,230 (2024: £27,000) as at the year end.

16
Directors' transactions

At the year end, a director owed the company an amount of £13,229 (2024: £13,848). The loan was interest free.

17
Controlling party

The company and group is controlled by W Harris, by virtue of his 100% shareholding.

2025-03-312024-04-01falsefalseCCH SoftwareCCH Accounts Production 2025.200No description of principal activityW HarrisM Gilbertfalse11018685bus:Consolidated2024-04-012025-03-31110186852024-04-012025-03-3111018685bus:Director12024-04-012025-03-3111018685bus:Director22024-04-012025-03-3111018685bus:RegisteredOffice2024-04-012025-03-3111018685bus:Consolidated2025-03-31110186852025-03-3111018685bus:Consolidated2024-03-31110186852024-03-3111018685core:Goodwillbus:Consolidated2025-03-3111018685core:NegativeGoodwillbus:Consolidated2025-03-3111018685core:ComputerSoftwarebus:Consolidated2025-03-3111018685core:Goodwillbus:Consolidated2024-03-3111018685core:NegativeGoodwillbus:Consolidated2024-03-3111018685core:ComputerSoftwarebus:Consolidated2024-03-3111018685core:ComputerSoftware2025-03-3111018685core:ComputerSoftware2024-03-3111018685core:OtherPropertyPlantEquipmentbus:Consolidated2025-03-3111018685core:OtherPropertyPlantEquipmentbus:Consolidated2024-03-3111018685core:OtherPropertyPlantEquipment2025-03-3111018685core:ShareCapitalbus:Consolidated2025-03-3111018685core:ShareCapitalbus:Consolidated2024-03-3111018685core:RetainedEarningsAccumulatedLossesbus:Consolidated2025-03-3111018685core:RetainedEarningsAccumulatedLossesbus:Consolidated2024-03-3111018685core:ShareCapital2025-03-3111018685core:ShareCapital2024-03-3111018685core:OtherMiscellaneousReserve2025-03-3111018685core:OtherMiscellaneousReserve2024-03-3111018685core:RetainedEarningsAccumulatedLosses2025-03-3111018685core:RetainedEarningsAccumulatedLosses2024-03-3111018685core:ShareCapitalbus:Consolidated2023-03-31110186852023-03-3111018685core:ShareCapital2023-03-3111018685core:RetainedEarningsAccumulatedLosses2023-03-31110186852023-04-012024-03-3111018685core:Goodwill2024-04-012025-03-3111018685core:IntangibleAssetsOtherThanGoodwill2024-04-012025-03-3111018685core:ComputerSoftware2024-04-012025-03-3111018685core:FurnitureFittings2024-04-012025-03-3111018685core:ComputerEquipment2024-04-012025-03-3111018685core:Goodwillbus:Consolidated2024-03-3111018685core:NegativeGoodwillbus:Consolidated2024-03-3111018685core:ComputerSoftwarebus:Consolidated2024-03-3111018685bus:Consolidated2024-03-3111018685core:ComputerSoftware2024-03-3111018685core:Goodwillcore:InternallyGeneratedIntangibleAssetsbus:Consolidated2024-04-012025-03-3111018685core:NegativeGoodwillcore:InternallyGeneratedIntangibleAssetsbus:Consolidated2024-04-012025-03-3111018685core:ComputerSoftwarecore:InternallyGeneratedIntangibleAssetsbus:Consolidated2024-04-012025-03-3111018685core:InternallyGeneratedIntangibleAssetsbus:Consolidated2024-04-012025-03-3111018685core:ComputerSoftwarecore:InternallyGeneratedIntangibleAssets2024-04-012025-03-3111018685core:Goodwillbus:Consolidated2024-04-012025-03-3111018685core:NegativeGoodwillbus:Consolidated2024-04-012025-03-3111018685core:ComputerSoftwarebus:Consolidated2024-04-012025-03-3111018685core:OtherPropertyPlantEquipmentbus:Consolidated2024-03-3111018685core:OtherPropertyPlantEquipment2024-03-3111018685core:OtherPropertyPlantEquipmentbus:Consolidated2024-04-012025-03-3111018685core:OtherPropertyPlantEquipment2024-04-012025-03-3111018685core:Subsidiary12024-04-012025-03-3111018685core:Subsidiary22024-04-012025-03-3111018685core:Subsidiary32024-04-012025-03-3111018685core:Subsidiary42024-04-012025-03-3111018685core:Subsidiary52024-04-012025-03-3111018685core:Subsidiary62024-04-012025-03-3111018685core:Subsidiary72024-04-012025-03-3111018685core:Subsidiary112024-04-012025-03-3111018685core:Subsidiary222024-04-012025-03-3111018685core:Subsidiary332024-04-012025-03-3111018685core:Subsidiary442024-04-012025-03-3111018685core:Subsidiary552024-04-012025-03-3111018685core:Subsidiary662024-04-012025-03-3111018685core:Subsidiary772024-04-012025-03-3111018685core:CurrentFinancialInstruments2025-03-3111018685core:CurrentFinancialInstruments2024-03-3111018685core:CurrentFinancialInstrumentsbus:Consolidated2025-03-3111018685core:CurrentFinancialInstrumentsbus:Consolidated2024-03-3111018685core:Non-currentFinancialInstrumentsbus:Consolidated2025-03-3111018685core:Non-currentFinancialInstrumentsbus:Consolidated2024-03-3111018685core:Non-currentFinancialInstruments2025-03-3111018685core:Non-currentFinancialInstruments2024-03-3111018685core:CurrentFinancialInstrumentscore:WithinOneYearbus:Consolidated2025-03-3111018685core:CurrentFinancialInstrumentscore:WithinOneYearbus:Consolidated2024-03-3111018685core:CurrentFinancialInstrumentscore:WithinOneYear2025-03-3111018685core:CurrentFinancialInstrumentscore:WithinOneYear2024-03-3111018685core:Non-currentFinancialInstrumentscore:AfterOneYearbus:Consolidated12025-03-3111018685core:Non-currentFinancialInstrumentscore:AfterOneYearbus:Consolidated12024-03-3111018685core:Non-currentFinancialInstrumentscore:AfterOneYear22025-03-3111018685core:Non-currentFinancialInstrumentscore:AfterOneYear22024-03-3111018685core:Non-currentFinancialInstrumentscore:AfterOneYearbus:Consolidated2025-03-3111018685core:Non-currentFinancialInstrumentscore:AfterOneYearbus:Consolidated2024-03-3111018685core:Non-currentFinancialInstrumentscore:AfterOneYear2025-03-3111018685core:Non-currentFinancialInstrumentscore:AfterOneYear2024-03-3111018685bus:PrivateLimitedCompanyLtd2024-04-012025-03-3111018685bus:FRS1022024-04-012025-03-3111018685bus:Audited2024-04-012025-03-3111018685bus:ConsolidatedGroupCompanyAccounts2024-04-012025-03-3111018685bus:SmallCompaniesRegimeForAccounts2024-04-012025-03-3111018685bus:FullAccounts2024-04-012025-03-31xbrli:purexbrli:sharesiso4217:GBP